Payment overview · 2025
General Payments
$948.38
58 reported records · 15 companies
Healthcare provider profile · identity verified
Steven J Delee, DO
Allopathic & Osteopathic Physicians|Family Medicine · CARMEL, IN · NPI 1407845001
Verified facts
What the public records show
CMS Open Payments records show Steven J Delee, DO received $948.38 in general payments during 2025 across 58 reported records.
ABBVIE INC. accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ingrezza, Jardiance, Linzess, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 674 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $311.14 | 32.8% | 32 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $276.70 | 29.2% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.72 | 8.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.21 | 4.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.86 | 4.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.11 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.21 | 2.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $21.61 | 2.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.43 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.61 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.19 | 1.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.91 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.57 | 1.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.53 | 1.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.58 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $727.40 | 56 |
| Education | $220.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $172.90 | 21 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $128.69 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.29 | 16 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.72 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $55.72 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.21 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.86 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.86 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $28.15 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $9.55 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $9.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 674 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 164 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
674 | 62 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1935 | 305 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1142 | 163 |
| Gabapentin | Gabapentin | 1097 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 975 | 150 |
| Pantoprazole Sodium | Pantoprazole Sodium | 890 | 103 |
| Furosemide | Furosemide | 803 | 104 |
| Metformin Hcl | Metformin Hcl | 783 | 118 |
| Lisinopril | Lisinopril | 725 | 112 |
| Eliquis | Apixaban | 674 | 62 |
| Losartan Potassium | Losartan Potassium | 621 | 92 |
| Metoprolol Tartrate | Metoprolol Tartrate | 609 | 74 |
| Buspirone Hcl | Buspirone Hcl | 595 | 63 |
| Potassium Chloride | Potassium Chloride | 565 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 543 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 521 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 518 | 87 |
| Sertraline Hcl | Sertraline Hcl | 447 | 74 |
| Trazodone Hcl | Trazodone Hcl | 423 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 388 | 63 |
| Donepezil Hcl | Donepezil Hcl | 377 | 49 |
| Mirtazapine | Mirtazapine | 377 | 50 |
| Omeprazole | Omeprazole | 370 | 88 |
| Divalproex Sodium | Divalproex Sodium | 369 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 325 | 46 |
| Xarelto | Rivaroxaban | 297 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 284 | 47 |
| Olanzapine | Olanzapine | 266 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 257 | 49 |
| Allopurinol | Allopurinol | 253 | 41 |
| Famotidine | Famotidine | 247 | 48 |
| Montelukast Sodium | Montelukast Sodium | 247 | 37 |
| Carvedilol | Carvedilol | 243 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 224 | 40 |
| Alendronate Sodium | Alendronate Sodium | 217 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 216 | 24 |
| Levetiracetam | Levetiracetam | 209 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 77 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 203 | 33 |
| Alprazolam | Alprazolam | 170 | 30 |
| Atenolol | Atenolol | 165 | 14 |
| Jardiance | Empagliflozin | 164 | 24 |
| Meloxicam | Meloxicam | 163 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 163 | 33 |
| Risperidone | Risperidone | 155 | 22 |
| Lamotrigine | Lamotrigine | 153 | 11 |
| Torsemide | Torsemide | 150 | 19 |
| Clonidine Hcl | Clonidine Hcl | 145 | 20 |
| Prednisone | Prednisone | 142 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 138 | 21 |
| Tramadol Hcl | Tramadol Hcl | 135 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 132 | 35 |
| Spironolactone | Spironolactone | 129 | 37 |
| Topiramate | Topiramate | 129 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 54 |
| Memantine Hcl | Memantine Hcl | 117 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 117 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 24 |
| Simvastatin | Simvastatin | 105 | 26 |
| Clonazepam | Clonazepam | 104 | 18 |
| Baclofen | Baclofen | 103 | 17 |
| Cephalexin | Cephalexin | 102 | 62 |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 59 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 96 | 17 |
| Bupropion Xl | Bupropion Hcl | 95 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 23 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 91 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 30 |
| Midodrine Hcl | Midodrine Hcl | 87 | 15 |
| Methylprednisolone | Methylprednisolone | 86 | 67 |
| Hydrocortisone | Hydrocortisone | 85 | 13 |
| Ibuprofen | Ibuprofen | 84 | 20 |
| Ezetimibe | Ezetimibe | 83 | 20 |
| Entresto | Sacubitril/Valsartan | 77 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 77 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 50 |
| Myrbetriq | Mirabegron | 75 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 72 | 29 |
| Loperamide | Loperamide Hcl | 72 | 33 |
| Nystatin | Nystatin | 72 | 49 |
| Pentoxifylline | Pentoxifylline | 70 | suppressed |
| Azithromycin | Azithromycin | 68 | 54 |
| Ondansetron Odt | Ondansetron | 68 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 26 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 64 | 14 |
| Glipizide Er | Glipizide | 64 | 14 |
| Trulicity | Dulaglutide | 64 | 17 |
| Metformin Hcl Er | Metformin Hcl | 63 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 61 | 16 |
| Oxcarbazepine | Oxcarbazepine | 60 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 59 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 58 | suppressed |
| Nitroglycerin | Nitroglycerin | 57 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 12 |
| Lithium Carbonate | Lithium Carbonate | 56 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 55 | suppressed |
| Finasteride | Finasteride | 55 | 18 |
| Lorazepam | Lorazepam | 55 | 24 |
| Primidone | Primidone | 54 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 13 |
| Glyburide | Glyburide | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 52 | suppressed |
| Acyclovir | Acyclovir | 51 | 21 |
| Albuterol Sulfate | Albuterol Sulfate | 50 | 23 |
| Amoxicillin | Amoxicillin | 50 | 47 |
| Glipizide | Glipizide | 50 | suppressed |
| Clozapine | Clozapine | 49 | suppressed |
| Diazepam | Diazepam | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 45 | 43 |
| Meclizine Hcl | Meclizine Hcl | 44 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 19 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Novolog Flexpen | Insulin Aspart | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 26 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 42 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 41 | suppressed |
| Ozempic | Semaglutide | 41 | 11 |
| Lithium Carbonate Er | Lithium Carbonate | 40 | suppressed |
| Calcium Acetate | Calcium Acetate | 39 | suppressed |
| Scopolamine | Scopolamine | 39 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Gemtesa | Vibegron | 36 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 11 |
| Tradjenta | Linagliptin | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 26 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | 13 |
| Ketoconazole | Ketoconazole | 25 | 11 |
| Olanzapine Odt | Olanzapine | 25 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | 12 |
| Invokana | Canagliflozin | 23 | suppressed |
| Nystop | Nystatin | 23 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 23 | 14 |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 22 | 22 |
| Mupirocin | Mupirocin | 22 | 20 |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Acetazolamide | Acetazolamide | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 14 |
| Ramelteon | Ramelteon | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | 19 |
| Potassium Citrate Er | Potassium Citrate | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 18 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 17 | 17 |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 11 |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Alprazolam Er | Alprazolam | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $948.38 · 58 records | ABBVIE INC. | ACCRUFER, AUSTEDO XR, CAPLYTA, CREON, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, HETLIOZ, INGREZZA, JARDIANCE, LINZESS, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, XYOSTED | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error